Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE ...
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for ...
Buy Rating for Mersana Therapeutics: Promising Efficacy and Safety of Emi-Le ADC Amid Stock Price Volatility
BTIG analyst Justin Zelin has reiterated their bullish stance on MRSN stock, giving a Buy rating yesterday.Stay Ahead of the Market:Discover ...
Mersana Therapeutics: Promising Clinical Data and Strong Financial Position Justify Buy Rating
Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target ...
Mersana falls after early-stage trial data for lead cancer therapy
Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...
Mersana Therapeutics, Inc.: Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...
Mersana Shares Rise on Advances With Breast-Cancer Treatment
Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...
kalkinemedia1d
Mersana Therapeutics (NASDAQ: MRSN) Announces Positive Initial Clinical Data for Emi-Le in Cancer Treatment
Announces Positive Initial Clinical Data for Emi-Le in Cancer Treatment ...
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Target Price from Analysts
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight ...
bovnews3d
Mersana Therapeutics Inc (MRSN) Stock Sees Market Value Hit $166.80 million: What Are the Implications?
Mersana Therapeutics Inc (MRSN) stock saw a decline, ending the day at $1.36 which represents a decrease of $-0.03 or -2.16% from the prior close of $1.39. The stock opened at $1.41 and touched a low ...
bovnews6d
Mersana Therapeutics Inc (MRSN) Stock Settles at $1.39: What’s Contributing to This Price Point?
Citigroup has recently resumed Mersana Therapeutics Inc (MRSN) stock to Buy rating, as announced on November 15, 2024, according to Finviz. Earlier, on March 19, 2024, JP Morgan had raised the stock ...